Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus PCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN STEARATE versus PCE.
ERYTHROMYCIN STEARATE vs PCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
PCE (erythromycin) binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptides.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
Erythromycin ethylsuccinate (PCE) typical adult dose: 400 mg orally every 6 hours or 800 mg orally every 12 hours. Maximum 4 g/day.
None Documented
None Documented
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to 7-10 hours in renal impairment (CrCl <30 mL/min).
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Primarily renal (about 70-80% as unchanged drug and metabolites via glomerular filtration and tubular secretion); minor biliary/fecal elimination (10-15%).
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic